Chemotherapy Added to Immunotherapy Improves Survival in NSCLC Patients
Current recommendations for first-line therapy for patients with metastatic non–small cell lung cancer (NSCLC) includes checkpoint inhibitor monotherapy, dual checkpoint inhibition, or in combination with chemotherapy. In a recently published study, researchers compared outcomes with combination chemo-immunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC. Read more.

Study Reveals EGFR Positivity Poor Predictor of Recurrence in NSCLC
Since risk factors for recurrence in early-stage epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC) remains undefined, researchers conducted a study to determine clinicopathologic characteristics and recurrence patterns of resected early-stage EGFR-positive NSCLC, using wildtype EGFR as a comparator cohort, and to identify features linked with recurrence. Read more.

Risks Associated With Concomitant Radiotherapy and Immune Checkpoint Inhibitors
While the use of immune checkpoint inhibitors (ICIs) has enhanced the survival of patients with cancer, their use has also been linked with augmented risk for immune-related adverse events. To date, whether concomitant treatment with ICIs and radiotherapy increases toxic effects remains unknown. Researchers conducted a retrospective cohort study to explore the safety profile of ICIs with radiotherapy. Read more.